Gyre Therapeutics Income Statement (2010-2026) | GYRE

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Revenue & cost
Revenue (Quarter)	2.30M	2.40M	0.79M			101.50M	24.93M	29.33M	32.04M	27.15M	27.17M	25.23M	25.49M	27.87M	22.06M	26.77M	30.56M	37.20M	22.52M	29.11M
Cost of Revenue (Quarter)	2.31M	2.45M	0.80M			4.00M	1.12M	1.08M	1.18M	1.25M	0.98M	0.77M	0.96M	1.18M	0.89M	1.15M	1.63M	1.74M	1.23M	2.21M
Gross Profit (Quarter)	-0.01M	-0.05M	-0.00M			97.50M	23.81M	28.25M	30.86M	25.90M	26.19M	24.45M	24.53M	26.70M	21.16M	25.62M	28.94M	35.45M	21.29M	26.90M
Operating items
Research & Development (Quarter)	20.35M	-50.15M	9.70M	1.87M	0.80M	41.86M	2.63M	3.57M	13.93M	-30.91M	2.18M	14.41M	2.77M	49.20M	3.10M	3.42M	2.36M	23.82M	6.74M	13.75M
Selling, General & Administrative (Quarter)	4.87M	4.16M	4.99M	3.84M	4.36M	4.17M	1.74M	1.71M	1.16M	10.05M	3.40M	3.42M	3.82M	5.46M	4.96M	4.83M	4.32M	6.70M	7.22M	7.87M
Restructuring Costs (Quarter)																0.00M				0.01M
Other Operating Expenses (Quarter)	2.31M	68.74M	0.80M	57.24M		-57.25M	4.74M		-0.53M	-2.17M	13.52M	-0.07M		0.00M	11.73M	-0.00M	-0.00M	-0.00M	17.92M	21.84M
Operating Expenses (Quarter)	27.53M	22.75M	15.49M	-51.53M	5.17M	123.96M	18.27M	24.36M	19.28M	118.78M	19.10M	21.26M	20.30M	27.21M	19.79M	23.45M	23.64M	40.75M	31.87M	43.47M
Operating Income (Quarter)	-25.23M	-20.31M	-14.70M	51.53M	-5.17M	-22.46M	6.66M	4.97M	12.76M	-91.63M	8.07M	3.19M	4.23M	0.67M	2.27M	2.17M	6.92M	0.12M	-9.36M	-14.36M
EBIT (Quarter)	-25.23M	-20.31M	-14.70M	51.53M	-5.17M	-22.46M	6.66M	4.97M	12.76M	-91.63M	8.07M	3.19M	4.23M	0.67M	2.27M	2.17M	6.92M	0.12M	-9.36M	-14.36M
Non-operating items
Interest & Investment Income (Quarter)	-0.01M	-0.02M	0.17M	0.10M	0.28M	0.17M	0.10M	0.07M	0.05M
Other Non Operating Income (Quarter)	-0.02M	-0.02M	-0.02M	0.02M	-0.00M	0.86M	0.07M	0.63M	-1.33M	-0.24M	0.12M	-0.07M	-0.07M	-1.63M	0.11M	-0.14M	0.73M	-2.19M	0.03M	-0.94M
Non Operating Income (Quarter)	0.01M	0.00M	0.00M	0.09M	0.28M	0.17M
Net income details
EBT (Quarter)	-27.71M	-20.99M	-14.54M	51.63M	-4.88M	-22.80M	6.27M	5.85M	11.19M	-100.28M	12.48M	6.04M	3.93M	0.77M	4.63M	2.24M	7.63M	-0.07M	-9.24M	-14.43M
Tax Provisions (Quarter)						5.99M	2.05M	2.08M	3.68M	0.70M	2.55M	1.50M	1.07M	0.20M	0.90M	0.66M	1.69M	-0.22M	0.62M	-0.16M
Profit After Tax (Quarter)	-25.24M	-20.33M	-14.54M	51.63M	-4.88M	-27.90M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	0.57M	3.73M	1.58M	5.94M	-1.32M	-9.86M	-14.27M
Income from Non-Controlling Interests (Quarter)							1.97M	1.92M	3.53M	0.03M	2.40M	1.01M	1.73M	0.67M	1.04M	1.13M	2.33M	0.36M	-1.17M	-3.67M
Income from Continuing Operations (Quarter)	-27.71M	-20.99M	-14.54M	51.63M	-4.88M	-28.79M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	0.57M	3.73M	1.58M	5.94M	0.16M	-9.86M	-14.27M
Consolidated Net Income (Quarter)	-27.71M	-20.99M	-14.54M	51.63M	-4.88M	-28.79M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	0.57M	3.73M	1.58M	5.94M	0.16M	-9.86M	-14.27M
Income towards Parent Company (Quarter)	-27.71M	-20.99M	-14.54M	51.63M	-4.88M	-28.79M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	0.57M	3.73M	1.58M	5.94M	0.16M	-9.86M	-14.27M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-25.24M	-20.99M	-14.54M	51.63M	-4.88M	-29.91M	2.24M	1.85M	3.98M	-101.01M	7.53M	3.53M	1.12M	-0.10M	2.70M	0.44M	3.61M	-1.72M	-8.69M	-11.66M
Additional items
EPS (Basic) (Quarter)	-12.06	-10.28	-6.93	24.60	-2.33	-14.22	0.89	0.74	1.57	-1.53	0.09	0.04	0.01	0.00	0.03	0.00	0.04	-0.02	-0.10	-0.12
EPS (Diluted) (Quarter)	-12.06	-10.28	-6.93	24.60	-2.33	-14.22	0.89	0.74	1.57	-1.53	0.07	0.03	0.01	0.00	0.03	0.00	0.03	-0.02	-0.10	-0.12
Shares Outstanding (Quarter)	2.09M	2.04M	2.10M	2.10M	2.10M	2.10M	2.52M	2.52M	2.53M	65.83M	83.27M	85.50M	85.64M	85.09M	86.42M	89.12M	90.85M	89.34M	91.32M	100.64M
Shares Outstanding (Diluted) (Quarter)	2.09M	2.04M	2.10M	2.10M	2.10M	2.10M	2.53M	2.52M	2.53M	65.83M	102.59M	104.33M	102.64M	102.29M	101.97M	102.70M	103.97M	103.18M	91.34M	100.64M
Shares Outstanding (Entity) (Quarter)	2.09M	2.09M	2.10M	2.10M	2.10M	2.52M	2.52M	2.53M	2.53M	76.60M	85.42M	85.54M	85.77M	86.31M	87.64M	90.82M	90.89M	91.31M	91.34M	111.51M
EBITDA (Quarter)	-25.23M	-20.31M	-14.70M	51.53M	-5.17M	-22.46M	6.66M	4.97M	12.76M	-91.63M	8.07M	3.19M	4.23M	0.67M	2.27M	2.17M	6.92M	0.12M	-9.36M	-14.36M
Interest Expenses (Quarter)	2.48M	0.66M	0.50M	1.44M	0.01M	-0.91M	0.64M	-0.40M	0.12M	0.21M	0.32M	2.09M	1.91M	0.24M	0.64M	1.45M	1.21M	0.26M	0.84M	4.29M
Tax Rate (Quarter)						-26.26%	32.75%	35.60%	32.87%	-0.70%	20.40%	24.81%	27.33%	26.30%	19.44%	29.58%	22.19%	339.39%	-6.72%	1.14%

Research Tools

Datasets

Plans

Developers

Gyre Therapeutics Income Statement (2010-2026) | GYRE

Research Tools

Datasets

Plans

Developers

Gyre Therapeutics Income Statement (2010-2026) | GYRE

Create an account

Sign In

Reset Password